Alexandria (ARE) Q4 2025 earnings review
Capitulation: Dividend Slashed 45% as Earnings Outlook Collapses
Alexandria Real Estate Equities has initiated a painful structural reset. Acknowledging a 'difficult environment' and 'unwanted oversupply,' management slashed the dividend by 45% to preserve $410 million in annual liquidity. The 2025 results showed cracks—Occupancy fell to 90.9% and cash rental spreads turned negative (-5.2%)—but the 2026 guidance is the real shock. Management projects 2026 FFO to plummet ~29% to $6.40 per share, driven by aggressive asset sales and deteriorating same-store performance. A massive $1.7 billion impairment charge in Q4 signals a 'kitchen sink' approach to clearing overvalued assets from the books.
🐂 Bull Case
The 45% dividend cut and $1.47B in Q4 dispositions prioritize survival and credit rating protection. Retaining $475M+ in annual cash flow reduces reliance on capital markets during a downturn.
By taking a $1.7B impairment and resetting guidance drastically lower, management may have cleared the decks of bad news, potentially setting a floor for the stock.
🐻 Bear Case
The thesis of resilient life science demand has fractured. With rental spreads turning negative (-5.2%) and occupancy guiding to ~88.5% for 2026, ARE has lost its pricing power.
To fix the balance sheet, ARE is selling assets at 6-7% yields while 2026 FFO is guided down nearly 30%. The company is shrinking significantly to save the core.
⚖️ Verdict: 🔴🔴
Strong Sell / Reversing. The dividend cut is a major thesis-breaker for income investors. While the balance sheet moves are prudent for survival, the operational metrics (negative spreads, falling occupancy) and the ~30% drop in projected earnings indicate the bottom is not yet in.
Key Themes
Pricing Power Evaporates
For the first time in recent history, cash rental spreads turned negative. In 24Q4, spreads were +3.3%, but in 25Q4 they dropped to -5.2%. This signals that ARE is forced to offer lower rents to maintain occupancy, validating concerns about life science oversupply.
Massive Asset Impairments
ARE recorded a staggering $1.71 billion impairment charge in Q4, primarily related to non-core assets and land held for sale (e.g., Gateway Blvd in South San Francisco, Seaport land). This confirms that book values for development land and non-Megacampus assets were significantly inflated relative to current market reality.
Accelerating Dispositions
The company completed $1.47 billion in dispositions in Q4 alone, bringing the FY25 total to $1.8 billion. This liquidity is critical, but it creates a massive earnings headwind. They are effectively shrinking the company to pay down debt and fund the remaining capex pipeline.
Occupancy Slide Continues
Occupancy fell from 94.6% in 24Q4 to 90.9% in 25Q4. More concerning is the 2026 guidance, which implies a further drop to a midpoint of 88.5%. The 'Megacampus' resilience narrative is struggling against the reality of tenant lease expirations and consolidations.
AstraZeneca & Large Pharma Reliance
A key bright spot remains large pharma. The 171,239 RSF lease with AstraZeneca in Maryland and their ongoing expansion ($2B investment in MD) highlights that while biotech struggles, mega-cap pharma continues to invest in manufacturing and R&D.
Cost Cutting Focus
G&A expenses dropped to 5.6% of NOI (lowest in 10 years), with $51M in savings realized in 2025. Management guides for another $76M in cumulative savings through 2026. This austerity is necessary but indicates a shift from growth to survival mode.
Other KPIs
Decelerating. Down 9.6% YoY vs $2.39 in 24Q4. The decline is accelerating as the impact of asset sales and lower occupancy hits the bottom line.
Rising. Up from 5.2x in 24Q4. While 5.7x is not distressed, the increase despite massive asset sales shows that EBITDA is falling faster than debt is being paid off. Management targets returning to ~5.6x-6.2x in 2026.
Reversing. This metric turned negative in Q4 (vs +6.3% in 24Q4) and is guided to plummet to -8.5% (midpoint) in 2026. This is the clearest indicator of operational deterioration.
Guidance
Decelerating violently. The midpoint ($6.40) represents a ~29% decline from 2025 levels ($9.01). This massive reset resets the valuation baseline for the stock.
Decelerating. A shocking guide down from +0.9% in FY25. Management cites lease expirations, free rent burn-off, and negative rental spreads as drivers.
Decelerating. Implies a further 200bps drop from current levels (90.9%). This suggests the bottom in leasing has not yet been reached.
Reversing. After years of positive spreads, ARE expects cash rents to roll down significantly in 2026, confirming a tenant's market.
Key Questions
Dividend Sustainability
You cut the dividend 45% to preserve capital. With 2026 FFO guiding to ~$6.40, is the new payout ratio (~45%) the long-term target, or should investors expect variability as disposals continue?
Negative Spreads Persistence
Cash rental rate guidance for 2026 is sharply negative (-12% to -4%). Is this driven by specific large expirations, or is this a structural reset in market rents across your core clusters?
Disposition Cap Rates vs Cost of Debt
You are guiding $2.9B in 2026 dispositions. With cap rates rising (8.5%-9.5% for non-core), are these sales dilutive to earnings, and how do you balance the need for liquidity against the destruction of FFO?
Impairment Outlook
Q4 saw a massive $1.7B impairment. Are there remaining assets on the books, particularly in non-Megacampus clusters, that are still carried above fair value?